Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.61 |
| ▸ | PPARG | P37231 | 4/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16473048 | 0.92 | PPARA (0.57) | PPARAPPARGACECTSKPPARD | |
| SCHEMBL31538727 | 0.92 | PPARA (0.54) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL30962415 | 0.84 | MAPT (0.60) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL6621271 | 0.84 | MAPT (0.60) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL1024713 | 0.84 | MAPT (0.60) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL4602404 | 0.84 | MAPT (0.60) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL955526 | 0.82 | PPARA (0.74) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL1312604 | 0.82 | PPARA (0.74) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL955527 | 0.82 | PPARA (0.74) | PPARAPPARGACECTSSCTSK | |
| SCHEMBL29865344 | 0.82 | ATM (0.60) | PPARAPPARGACECTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-7132434-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050026990-A1 | Novel metalloproteinase ihibitors | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
| EP-1444202-A1 | NOVEL METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040098-A1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026990-A1 | Novel metalloproteinase ihibitors | MMP12, MMP1, MMP16 | PPARA 3793/4885PPARG 3197/4885ACE 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.